Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother
Main Authors: Gangadhar, Tara C., Hwu, Wen-Jen, Postow, Michael A., Hamid, Omid, Daud, Adil, Dronca, Roxana, Joseph, Richard, O’Day, Steven J., Hodi, F.S., Pavlick, Anna C., Kluger, Harriet, Oxborough, Romina P., Yang, Aiming, Gazdoiu, Mihaela, Kush, Debra A., Ebbinghaus, Scot, Salama, April K.S.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2017
Assuntos:
Basic Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5647109/
https://ncbi.nlm.nih.gov/pubmed/29028788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000186
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados